Trial Review

Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements. New passwords must include at least one lowercase letter, one uppercase letter, one number and one special character (e.g. !#$%&@).
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06100627




Registration number
NCT06100627
Ethics application status
Date submitted
17/10/2023
Date registered
25/10/2023
Date last updated
10/05/2024

Titles & IDs
Public title
A Pharmacodynamic Effect Study of AP301 in Healthy Volunteers
Scientific title
A Randomized, Open-Label, Parallel Group, Phase 1 Study to Assess the Pharmacodynamic Effect of AP301 on Urinary Phosphorus Excretion in Healthy Volunteers
Secondary ID [1] 0 0
AP301-PD-01
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Healthy Subjects 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - AP301

Experimental: 2.10 g/day of AP301 -

Experimental: 4.20 g/day of AP301 -

Experimental: 6.30 g/day of AP301 -

Experimental: 8.40 g.day of AP301 -


Treatment: Drugs: AP301
Orally administered
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Urinary phosphorus excretion during AP301 administration
Assessment method [1] 0 0
Average daily urinary phosphorus excretion during the 3 consecutive days of AP301 treatment
Timepoint [1] 0 0
From the Day 1 to Day 4 after dosing, assessed up to 3 days
Primary outcome [2] 0 0
Effect of AP301 on urinary phosphorus excretion
Assessment method [2] 0 0
Change of average daily urinary phosphorus excretion from 3 days before treatment to 3 days during treatment.
Timepoint [2] 0 0
From Day -3 to Day 4 after dosing, assessed up to 6 days
Primary outcome [3] 0 0
Urinary calcium excretion during AP301 administration
Assessment method [3] 0 0
Average daily urinary calcium excretion during the 3 consecutive days of AP301 treatment.
Timepoint [3] 0 0
From the Day 1 to Day 4 after dosing, assessed up to 3 days
Primary outcome [4] 0 0
Effect of AP301 on urinary calcium excretion
Assessment method [4] 0 0
Change of average daily urinary calcium excretion from 3 days before treatment to 3 days during treatment.
Timepoint [4] 0 0
From Day -3 to Day 4 after dosing, assessed up to 6 days
Primary outcome [5] 0 0
Effect of AP301 on serum phosphorus and calcium
Assessment method [5] 0 0
Changes of serum phosphorus and serum calcium from baseline to end of treatment.
Timepoint [5] 0 0
From Day -3 to Day 4 after dosing, assessed up to 6 days
Secondary outcome [1] 0 0
Incidence and severity of adverse events (AEs)
Assessment method [1] 0 0
Number of participants with adverse events (AEs) and the intensity of adverse events. Number of participants with serious adverse events (SAEs) and the intensity of adverse events.
Timepoint [1] 0 0
From screening to hospitalization and follow up periods, assessed up to 43 days
Secondary outcome [2] 0 0
Changes in clinical laboratory values
Assessment method [2] 0 0
Changes and their clinical meaningfulness in clinical laboratory values: Hematology, Biochemistry, Urinalysis
Timepoint [2] 0 0
From screening to hospitalization and follow up periods, assessed up to 43 days
Secondary outcome [3] 0 0
Abnormal electrocardiogram (ECG) readings and their clinical meaningfulness
Assessment method [3] 0 0
ECG intervals (PR \[PQ\], QRS, QT, QTcF) and heart rate
Timepoint [3] 0 0
From screening to hospitalization and follow up periods, assessed up to 43 days
Secondary outcome [4] 0 0
Changes of ECG parameters and their clinical meaningfulness
Assessment method [4] 0 0
ECG intervals (PR \[PQ\], QRS, QT, QTcF), heart rate, T-wave morphology and U-wave morphology.
Timepoint [4] 0 0
From screening to hospitalization and follow up periods, assessed up to 43 days
Secondary outcome [5] 0 0
Abnormal vital signs and their clinical meaningfulness
Assessment method [5] 0 0
Blood pressure, heart rate and body temperature
Timepoint [5] 0 0
From screening to hospitalization and follow up periods, assessed up to 43 days

Eligibility
Key inclusion criteria
Important

* Healthy male volunteers, 18-55 years of age
* Body mass index (BMI) 18-30 kg/m2 (exclusive) at screening.

Important
Minimum age
18 Years
Maximum age
55 Years
Sex
Males
Can healthy volunteers participate?
Yes
Key exclusion criteria
* Serum phosphorus is below 1.00 mmol/L at screening.
* History of significant gastrointestinal disease or disorder, major gastrointestinal surgeries, or cholecystectomy
* History or symptoms of any clinically significant kidney, liver, broncho-pulmonary, gastrointestinal, neurological, psychiatric, cardiovascular, endocrine/metabolic, hematological diseases, or cancer.
* History of specific allergies or allergic conditions or known allergies to the study drug as judged by the investigator, or any confirmed significant allergic reactions (urticaria or anaphylaxis) to any drug, or multiple drug allergies (non-active hay fever is acceptable). Allowing for childhood asthma, history of mild eczema that has had no flare ups for =5 years or is fully resolved.
* Known history of allergy to common food like milk or gluten, or lactose intolerance, or special diet habit for religious/life-style reasons, which might potentially jeopardize the participant's compliance of study diet.
* Any clinically significant concomitant disease, or condition or treatment that could interfere with the conduct of the study.
* Confirmed (based on the average of 3 separate resting blood pressure measurements, after at least 5 minutes rest) systolic blood pressure (BP) greater than 150 or less than 90 mmHg, and diastolic BP greater than 90 or less than 50 mmHg at screening.
* Clinically relevant ECG abnormalities on screening ECG.
* Estimated glomerular filtration rate (eGFR) = 70 mL/min/1.73 m2.
* Positive test at screening of any of the following: Hepatitis B (HBsAg), Hepatitis C (HCV Ab) or human immunodeficiency virus (HIV-1 or HIV-2 Ab).
* Alanine aminotransferase (ALT) or aspartate transaminase (AST) > 1.5 × upper limit of normal (ULN), or any other clinically significant abnormalities in laboratory test results at screening.
* Dosed with a small-molecule or biologic investigational drug within 30 days or 90 days, respectively, or 5 half-lives (whichever is the longer) prior to first dose of this study.
* Positive urine test for drugs of abuse and/or positive alcohol test at screening.
* Any medical or social conditions that, in the view of investigator, might potentially jeopardize the participant's compliance of study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
11/01/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
28/02/2024
Sample size
Target
Accrual to date
Final
32
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Nucleus Network Pty Ltd - Melbourne
Recruitment postcode(s) [1] 0 0
3004 - Melbourne

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Alebund Pty Ltd
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Public notes

Contacts
Principal investigator
Name 0 0
Sam Francis, Doctor
Address 0 0
Nucleus Network
Country 0 0
Phone 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT06100627